Lee et al. recently showed that for metastatic GIST patients treated with imatinib, valuable risk factors for OS and progression-free survival (PFS) are the size of the largest metastasis, tumor genotype, primary tumor mitotic count, Hb level and blood neutrophil count [34]. Here, GSTM1 is linked to gastrointestinal stromal tumor.